CA2370259A1 - Pyrrolidincarbonylamino cyclic disulfides - Google Patents

Pyrrolidincarbonylamino cyclic disulfides Download PDF

Info

Publication number
CA2370259A1
CA2370259A1 CA002370259A CA2370259A CA2370259A1 CA 2370259 A1 CA2370259 A1 CA 2370259A1 CA 002370259 A CA002370259 A CA 002370259A CA 2370259 A CA2370259 A CA 2370259A CA 2370259 A1 CA2370259 A1 CA 2370259A1
Authority
CA
Canada
Prior art keywords
compound
amino
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370259A
Other languages
English (en)
French (fr)
Inventor
Li Chen
Nader Fotouhi
David Young Jackson
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370259A1 publication Critical patent/CA2370259A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002370259A 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides Abandoned CA2370259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US60/130,215 1999-04-20
PCT/EP2000/003459 WO2000063234A2 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists

Publications (1)

Publication Number Publication Date
CA2370259A1 true CA2370259A1 (en) 2000-10-26

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370259A Abandoned CA2370259A1 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides

Country Status (15)

Country Link
US (1) US6265572B1 (cg-RX-API-DMAC7.html)
EP (1) EP1171452B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002542256A (cg-RX-API-DMAC7.html)
KR (1) KR100636481B1 (cg-RX-API-DMAC7.html)
CN (1) CN1167710C (cg-RX-API-DMAC7.html)
AR (1) AR023546A1 (cg-RX-API-DMAC7.html)
AT (1) ATE337331T1 (cg-RX-API-DMAC7.html)
AU (1) AU769294B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009838A (cg-RX-API-DMAC7.html)
CA (1) CA2370259A1 (cg-RX-API-DMAC7.html)
DE (1) DE60030266T2 (cg-RX-API-DMAC7.html)
ES (1) ES2269141T3 (cg-RX-API-DMAC7.html)
TR (1) TR200103004T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000063234A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108018B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US20090043126A1 (en) * 2005-02-28 2009-02-12 Jordi Bosch I Llado Process and Methods for the Preparation of Gabapentin and Its Intermediates
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2013057096A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
DE60030266D1 (de) 2006-10-05
EP1171452B1 (en) 2006-08-23
CN1167710C (zh) 2004-09-22
DE60030266T2 (de) 2007-07-19
US6265572B1 (en) 2001-07-24
WO2000063234A2 (en) 2000-10-26
KR20010108517A (ko) 2001-12-07
ES2269141T3 (es) 2007-04-01
KR100636481B1 (ko) 2006-10-18
CN1347419A (zh) 2002-05-01
TR200103004T2 (tr) 2002-01-21
WO2000063234A3 (en) 2001-01-18
AR023546A1 (es) 2002-09-04
EP1171452A2 (en) 2002-01-16
AU769294B2 (en) 2004-01-22
AU4748200A (en) 2000-11-02
ZA200108018B (en) 2003-03-26
BR0009838A (pt) 2002-01-08
JP2002542256A (ja) 2002-12-10
ATE337331T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
KR100615760B1 (ko) 엔-알카노일페닐알라닌 유도체
US6458844B2 (en) Diphenyl carbocyclic thioamide derivatives
RU2266901C2 (ru) 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
US5719296A (en) Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
EP0618223A2 (en) Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents
LT3626B (en) Compounds containing a fused bicycle ring and processing thereof
KR20050010514A (ko) 고지질혈증의 치료를 위한 티아제핀기를 포함하는 펩티드유도체
SK158196A3 (en) Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same
AU769294B2 (en) Pyrrolidincarbonylamino cyclic disulfides
PH26816A (en) Diol-containing renin inhibitors
US20110118172A1 (en) Metastin derivative and use thereof
CN104640860B (zh) 氮杂二氢吲哚
KR20150065718A (ko) 인돌린
JPH06199820A (ja) 三環及び四環式化合物
MXPA01010543A (en) Pyrrolidincarbonylamino cyclic disulfides
IE870861L (en) Azepine and thiazepine derivatives
MXPA00001743A (es) Derivados de n-alcanoilfenilalanina
MXPA01008376A (en) Thioamide derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued